Decibel Therapeutics CEO Steven Holtzman is really, officially retiring.
The departure of the longtime vet of Boston’s biotech scene — he was formerly an executive vice president at Biogen and CEO of the cancer-focused Infinity Pharmaceuticals — is part of a broader restructuring at Decibel. The company is also ditching some early discovery programs and narrowing its scientific focus to regenerating damaged cells and structures in the ear that cause hearing and balance disorders.
I am interested as a patient. I have idiopathic hearing loss in both ears caused by the death of the cells in my inner ears. I have tried to slow it by allergy shots and pomegranate juice drinks.
Comments are closed.